P. Peter Ghoroghchian

Dr. Peter Ghoroghchian is the co-founder of Ceptur Therapeutics and its President and Chief Executive Officer. He was previously Senior Vice President and Head of Therapeutic Development at Repertoire Immune Medicines (2019-2020), Chief Technology Officer at Poseida Therapeutics (NASDAQ: PSTX; 2016-2019), and Chief Scientific Officer at Vindico NanoBioTechnology (acquired by Poseida; 2009-2016). Earlier in his career, Dr. Ghoroghchian was an attending physician in the Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute as well as the Charles W. and Jennifer C. Johnson Clinical Investigator in the Koch Institute for Integrative Cancer Research at MIT. He earned his B.S. in chemical engineering from MIT followed by his Ph.D. and M.D. degrees from the University of Pennsylvania. After medical school, Dr. Ghoroghchian completed residency training in internal medicine at the Brigham and Women’s Hospital as well as fellowship training in hematology and adult medical oncology at the Dana-Farber Cancer Institute and at the Massachusetts General Hospital.